Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort

被引:8
作者
Yang, Hongxia [1 ,2 ]
Tian, Xiaolan [2 ]
Zhang, Lining [1 ,2 ]
Li, Wenli [2 ]
Liu, Qingyan [2 ]
Jiang, Wei [2 ]
Peng, Qinglin [2 ]
Wang, Guochun [1 ,2 ]
Lu, Xin [1 ,2 ]
机构
[1] Peking Univ, China Japan Friendship Sch Clin Med, Beijing 100029, Peoples R China
[2] China Japan Friendship Hosp, Dept Rheumatol, Yinghua East Rd, Beijing 100029, Peoples R China
关键词
Muscle biopsy; Idiopathic inflammatory myopathies; Immune-mediated necrotising myopathy; Pathological features; IDIOPATHIC INFLAMMATORY MYOPATHIES; DISEASE; DERMATOMYOSITIS; CLASSIFICATION; POLYMYOSITIS; MYOSITIS; MUTATION;
D O I
10.1186/s12891-022-05372-z
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Objective Immune-mediated necrotising myopathy (IMNM) is a subset of idiopathic inflammatory myopathies (IIM) characterized by significantly elevated creatine kinase level, muscle weakness and predominant muscle fibre necrosis in muscle biopsy. This study aimed to investigate the clinical and pathological characteristics of patients with IMNM in a single-centre muscle biopsy cohort. Methods A total of 860 patients who had muscle biopsy reports in our centre from May 2008 to December 2017 were enrolled in this study. IMNM was diagnosed according to the 2018 European Neuromuscular Centre (ENMC) clinicopathological diagnostic criteria for IMNM. Results The muscle biopsy cohort consisted of 531 patients with IIM (61.7%), 253 patients with non-IIM (29.4%), and 76 undiagnosed patients (8.8%). IIM cases were classified as IMNM (68[7.9%]), dermatomyositis (346[40.2%]), anti-synthetase syndrome (82[9.5%]), polymyositis (32[3.7%]), and sporadic inclusion body myositis (3[0.3%]). Limb girdle muscular dystrophy (LGMD) 2B and lipid storage myopathy (LSM) are the two most common non-IIM disorders in our muscle biopsy cohort. IMNM patients had a higher onset age (41.57 +/- 14.45 vs 21.66 +/- 7.86 and 24.56 +/- 10.78, p < .0001), shorter duration (21.79 +/- 26.01 vs 66.69 +/- 67.67 and 24.56 +/- 10.78, p < .0001), and more frequent dysphagia (35.3% vs. 3.4 and 6.3%, p = .001) than LGMD 2B and LSM patients. Muscle biopsy from IMNM showed more frequent muscle fibre necrosis (95.6% vs 72.4 and 56.3%, p < .0001), overexpression of major histocompatibility complex-I on sarcolemma (83.8% vs 37.9 and 12.9%, p < .0001), and CD4(+) T cell endomysia infiltration (89.7% vs 53.6 and 50%, p < .0001) compared with those from LGMD 2B and LSM patients. Conclusions It is easy to distinguish IMNM from other IIM subtypes according to clinical symptoms and myositis specific antibodies profiles. However, distinguishing IMNM from disorders clinically similar to non-IIM needs combined clinical, serological and pathological features.
引用
收藏
页数:10
相关论文
共 33 条
  • [1] Anderson GMJL., 2015, NEW ENGL MOURNAL MED, V311, P887
  • [2] POLYMYOSITIS AND DERMATOMYOSITIS .1.
    BOHAN, A
    PETER, JB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (07) : 344 - 347
  • [3] Chawla Jasvinder, 2011, Front Neurol, V2, P49, DOI 10.3389/fneur.2011.00049
  • [4] Chen HM, 2019, INT J MOL EPIDEMIOL, V10, P53
  • [5] Interstitial Lung Disease Associated With the Idiopathic Inflammatory Myopathies What Progress Has Been Made in the Past 35 Years?
    Connors, Geoffrey R.
    Christopher-Stine, Lisa
    Oddis, Chester V.
    Danoff, Sonye K.
    [J]. CHEST, 2010, 138 (06) : 1464 - 1474
  • [6] Gonorazky Hernan D, 2018, Handb Clin Neurol, V148, P549, DOI 10.1016/B978-0-444-64076-5.00036-3
  • [7] Hoogendijk Jessica E, 2004, Neuromuscul Disord, V14, P337, DOI 10.1016/j.nmd.2004.02.006
  • [8] An efficacy analysis of whole-body magnetic resonance imaging in the diagnosis and follow-up of polymyositis and dermatomyositis
    Huang, Zhen-guo
    Gao, Bao-xiang
    Chen, He
    Yang, Min-xing
    Chen, Xiao-liang
    Yan, Ran
    Lu, Xin
    Shi, Kai-ning
    Chan, Queenie
    Wang, Guo-chun
    [J]. PLOS ONE, 2017, 12 (07):
  • [9] The utility of muscle biopsy
    Lacomis D.
    [J]. Current Neurology and Neuroscience Reports, 2004, 4 (1) : 81 - 86
  • [10] The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies: An Open-Label Pilot Study
    Li, Sizhao
    Li, Wenli
    Jiang, Wei
    He, Linrong
    Peng, Qinglin
    Wang, Guochun
    Lu, Xin
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12